[R03DA07, theobromine, The risk or severity of adverse effects can be increased when Theobromine is combined with Linaclotide.]
[N05CA19, thiopental, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Thiopental.]
[N02AX01, tilidine, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Tilidine.]
[N02AX02, tramadol, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Tramadol.]
[C03DB02, triamterene, The risk or severity of adverse effects can be increased when Triamterene is combined with Linaclotide.]
[C03AA06, trichlormethiazide, The risk or severity of adverse effects can be increased when Trichlormethiazide is combined with Linaclotide.]
[A03AB12, mepenzolate, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Mepenzolate.]
[N05AA05, triflupromazine, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Triflupromazine.]
[N04AA01, trihexyphenidyl, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Trihexyphenidyl.]
[A03AA05, trimebutine, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Trimebutine.]
[N03AC02, trimethadione, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Trimethadione.]
[C02BA01, trimethaphan, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Trimethaphan.]
[A03BB01, butylscopolamine, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Butylscopolamine.]
[S01FA06, tropicamide, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Tropicamide.]
[M03AA02, tubocurarine, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Tubocurarine.]
[C08DA01, verapamil, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Verapamil.]
[C03BA10, xipamide, The risk or severity of adverse effects can be increased when Xipamide is combined with Linaclotide.]
[N05AE04, ziprasidone, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Ziprasidone.]
[G03AC10, drospirenone, The risk or severity of adverse effects can be increased when Drospirenone is combined with Linaclotide.]
[G04BD07, tolterodine, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Tolterodine.]
[M03AC04, atracurium, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Atracurium.]
[S01FA01, atropine, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Atropine.]
[N05CA04, barbital, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Barbital.]
[C08CA13, lercanidipine, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Lercanidipine.]
[R06AC06, thonzylamine, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Thonzylamine.]
[G04BD10, darifenacin, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Darifenacin.]
[C04AX11, bencyclane, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Bencyclane.]
[C03AA01, bendroflumethiazide, The risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Linaclotide.]
[A10BK02, canagliflozin, The risk or severity of adverse effects can be increased when Canagliflozin is combined with Linaclotide.]
[A06AX06, tegaserod, The risk or severity of adverse effects can be increased when Tegaserod is combined with Linaclotide.]
[N04AC01, benztropine, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Benzatropine.]
[C08EA02, bepridil, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Bepridil.]
[A10BK01, dapagliflozin, The risk or severity of adverse effects can be increased when Dapagliflozin is combined with Linaclotide.]
[A03BA03, hyoscyamine, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Hyoscyamine.]
[D11AA01, glycopyrronium, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Glycopyrronium.]
[A06AB04, phenolphthalein, The risk or severity of adverse effects can be increased when Phenolphthalein is combined with Linaclotide.]
[A06AH03, naloxegol, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Naloxegol.]
[N04AA02, biperiden, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Biperiden.]
[A06AG02, bisacodyl, The risk or severity of adverse effects can be increased when Linaclotide is combined with Bisacodyl.]
[A03AA09, difemerine, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Difemerine.]
[A07DA06, eluxadoline, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Eluxadoline.]
[A06AD03, magnesium peroxide, The risk or severity of adverse effects can be increased when Linaclotide is combined with Magnesium peroxide.]
[S01EC01, acetazolamide, The risk or severity of adverse effects can be increased when Acetazolamide is combined with Linaclotide.]
[N05CA05, aprobarbital, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Aprobarbital.]
[R06AB01, brompheniramine, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Brompheniramine.]
[C08CA01, amlodipine, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Amlodipine.]
[C03CA02, bumetanide, The risk or severity of adverse effects can be increased when Bumetanide is combined with Linaclotide.]
[N07BC01, buprenorphine, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Buprenorphine.]
[N02AF01, butorphanol, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Butorphanol.]
[A06AX07, plecanatide, The risk or severity of adverse effects can be increased when Linaclotide is combined with Plecanatide.]
[N04AA11, bornaprine, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Bornaprine.]
[C03DA03, canrenone, The risk or severity of adverse effects can be increased when Canrenone is combined with Linaclotide.]
[N05CA03, butobarbital, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Butobarbital.]
[A10BK04, ertugliflozin, The risk or severity of adverse effects can be increased when Ertugliflozin is combined with Linaclotide.]
[A06AC08, calcium polycarbophil, The risk or severity of adverse effects can be increased when Linaclotide is combined with Calcium polycarbophil.]
[A03AA03, camylofine, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Camylofin.]
[C07AG02, carvedilol, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Carvedilol.]
[R06AA06, chlorphenoxamine, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Chlorphenoxamine.]
[R03BB08, revefenacin, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Revefenacin.]
[A06AX05, prucalopride, The risk or severity of adverse effects can be increased when Prucalopride is combined with Linaclotide.]
[A06AB05, castor oil, The risk or severity of adverse effects can be increased when Linaclotide is combined with Castor oil.]
[C03BX03, cicletanine, The risk or severity of adverse effects can be increased when Cicletanine is combined with Linaclotide.]
[C03AA09, cyclothiazide, The risk or severity of adverse effects can be increased when Cyclothiazide is combined with Linaclotide.]
[A06AB03, danthron, The risk or severity of adverse effects can be increased when Dantron is combined with Linaclotide.]
[N02AX03, dezocine, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Dezocine.]
[N02AA08, dihydrocodeine, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Dihydrocodeine.]
[C08CA16, clevidipine, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Clevidipine.]
[A03AA08, dihexyverine, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Dihexyverine.]
[G04BD09, trospium, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Trospium.]
[C08CA17, levamlodipine, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Levamlodipine.]
[N02AX07, oliceridine, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Oliceridine.]
[C03AA04, chlorothiazide, The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Linaclotide.]
[N05AA01, chlorpromazine, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Chlorpromazine.]
[N05AF03, chlorprothixene, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Chlorprothixene.]
[C03BA04, chlorthalidone, The risk or severity of adverse effects can be increased when Chlorthalidone is combined with Linaclotide.]
[N06BX18, vinpocetine, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Vinpocetine.]
[N07CA02, cinnarizine, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Cinnarizine.]
[C03DA05, finerenone, The risk or severity of adverse effects can be increased when Finerenone is combined with Linaclotide.]
[C03BA03, clopamide, The risk or severity of adverse effects can be increased when Clopamide is combined with Linaclotide.]
[N05AH02, clozapine, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Clozapine.]
[S02DA02, cocaine, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Cocaine.]
[R05DA04, codeine, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Codeine.]
[M03AC05, hexafluorenium, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Hexafluronium.]
[A03AB10, hexocyclium, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Hexocyclium.]
[A03BB06, homatropine methylbromide, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Homatropine methylbromide.]
[S01FA05, homatropine, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Homatropine.]
[R06AX27, desloratadine, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Desloratadine.]
[C08CA09, lacidipine, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Lacidipine.]
[A06AD12, lactitol, The risk or severity of adverse effects can be increased when Linaclotide is combined with Lactitol.]
[N03AX09, lamotrigine, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Lamotrigine.]
[A06AD01, magnesium carbonate, The risk or severity of adverse effects can be increased when Linaclotide is combined with Magnesium carbonate.]
[C08CA11, manidipine, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Manidipine.]
[A03AA04, mebeverine, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Mebeverine.]
[N04AA03, methixene, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Metixene.]
[C04AX01, cyclandelate, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Cyclandelate.]
[C03DA04, eplerenone, The risk or severity of adverse effects can be increased when Eplerenone is combined with Linaclotide.]
[C03AA07, cyclopenthiazide, The risk or severity of adverse effects can be increased when Cyclopenthiazide is combined with Linaclotide.]
[S01FA04, cyclopentolate, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Cyclopentolate.]
[R06AX02, cyproheptadine, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Cyproheptadine.]
[C03XA02, conivaptan, The risk or severity of adverse effects can be increased when Conivaptan is combined with Linaclotide.]
[M03AC11, cisatracurium, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Cisatracurium.]
[R05DA06, normethadone, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Normethadone.]
[N06AB10, escitalopram, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Escitalopram.]
[G04BD08, solifenacin, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Solifenacin.]
[N06AA01, desipramine, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Desipramine.]
[N04AA08, dexetimide, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Dexetimide.]
[G04BD04, oxybutynin, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Oxybutynin.]
[A03AA01, oxyphencyclimine, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Oxyphencyclimine.]
[R05DA09, dextromethorphan, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Dextromethorphan.]
[N02AC01, dextromoramide, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Dextromoramide.]
[N06AB05, paroxetine, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Paroxetine.]
[N07BC06, heroin, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Diamorphine.]
[S01EC02, dichlorphenamide, The risk or severity of adverse effects can be increased when Diclofenamide is combined with Linaclotide.]
[A03AA07, dicyclomine, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Dicyclomine.]
[A03AX04, pinaverium, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Pinaverium.]
[A03AB14, pipenzolate, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Pipenzolate.]
[C03CA03, piretanide, The risk or severity of adverse effects can be increased when Piretanide is combined with Linaclotide.]
[C08CA03, isradipine, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Isradipine.]
[A03AB11, poldine, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Poldine.]
[N02AA03, hydromorphone, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Hydromorphone.]
[C08DB01, diltiazem, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Diltiazem.]
[R06AB03, dimethindene, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Dimetindene.]
[R06AA02, diphenhydramine, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Diphenhydramine.]
[A07DA01, diphenoxylate, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Diphenoxylate.]
[C01BA03, disopyramide, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Disopyramide.]
[C03XA01, tolvaptan, The risk or severity of adverse effects can be increased when Tolvaptan is combined with Linaclotide.]
[N06AA16, dothiepin, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Dosulepin.]
[N06AA12, doxepin, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Doxepin.]
[A06AB06, sennosides, USP, The risk or severity of adverse effects can be increased when Linaclotide is combined with Sennosides.]
[R06AA09, doxylamine, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Doxylamine.]
[V03AG05, sodium phosphate, The risk or severity of adverse effects can be increased when Linaclotide is combined with Sodium phosphate, monobasic.]
[A12CA02, sodium sulfate, The risk or severity of adverse effects can be increased when Linaclotide is combined with Sodium sulfate.]
[G04BD05, terodiline, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Terodiline.]
[G04BD01, emepronium, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Emepronium.]
[C03CA04, torsemide, The risk or severity of adverse effects can be increased when Torasemide is combined with Linaclotide.]
[A03AB08, tridihexethyl, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Tridihexethyl.]
[N04AA12, tropatepine, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Tropatepine.]
[S01GA03, xylometazoline, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Xylometazoline.]
[C08CA12, mepirodipine, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Barnidipine.]
[N03AX15, zonisamide, The risk or severity of adverse effects can be increased when Zonisamide is combined with Linaclotide.]
[N04AA05, profenamine, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Profenamine.]
[N03AD01, ethosuximide, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Ethosuximide.]
[S01XA06, ethylmorphine, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Ethylmorphine.]
[R06AX12, terfenadine, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Terfenadine.]
[C08CA02, felodipine, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Felodipine.]
[C08EA01, fendiline, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Fendiline.]
[R03CC04, fenoterol, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Fenoterol.]
[N02AB03, fentanyl, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Fentanyl.]
[G04BD02, flavoxate, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Flavoxate.]
[N07CA03, flunarizine, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Flunarizine.]
[N06AB03, fluoxetine, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Fluoxetine.]
[N05AF01, flupenthixol, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Flupentixol.]
[N05AG01, fluspirilene, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Fluspirilene.]
[M03AA01, alcuronium, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Alcuronium.]
[C03CA01, furosemide, The risk or severity of adverse effects can be increased when Furosemide is combined with Linaclotide.]
[M03AC02, gallamine, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Gallamine.]
[C08DA02, gallopamil, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Gallopamil.]
[N03AD03, methsuximide, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Methsuximide.]
[N01AH02, alfentanil, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Alfentanil.]
[A06AX01, glycerin, The risk or severity of adverse effects can be increased when Linaclotide is combined with Glycerin.]
[N05AH04, quetiapine, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Quetiapine.]
[B05CB03, magnesium citrate, The risk or severity of adverse effects can be increased when Linaclotide is combined with Magnesium citrate.]
[A12CD02, sodium monofluorophosphate, The risk or severity of adverse effects can be increased when Linaclotide is combined with Sodium fluorophosphate.]
[N05CA16, hexobarbital, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Hexobarbital.]
[C08CA10, nilvadipine, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Nilvadipine.]
[M02AA26, nimesulide, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Nimesulide.]
[C03AA03, hydrochlorothiazide, The risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Linaclotide.]
[R05DA03, hydrocodone, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Hydrocodone.]
[C03AA02, hydroflumethiazide, The risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Linaclotide.]
[A12BA02, potassium citrate, The risk or severity of adverse effects can be increased when Potassium citrate is combined with Linaclotide.]
[G04BD06, propiverine, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Propiverine.]
[A06AD21, sodium tartrate, The risk or severity of adverse effects can be increased when Linaclotide is combined with Sodium tartrate.]
[N01AH03, sufentanil, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Sufentanil.]
[N06AA02, imipramine, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Imipramine.]
[C03BA11, indapamide, The risk or severity of adverse effects can be increased when Indapamide is combined with Linaclotide.]
[A03AA30, piperidolate, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Piperidolate.]
[R06AE01, buclizine, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Buclizine.]
[C03BA02, quinethazone, The risk or severity of adverse effects can be increased when Quinethazone is combined with Linaclotide.]
[N01AB06, isoflurane, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Isoflurane.]
[N05AH03, olanzapine, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Olanzapine.]
[N04BB01, amantadine, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Amantadine.]
[A06AD11, lactulose, The risk or severity of adverse effects can be increased when Lactulose is combined with Linaclotide.]
[A06AX03, lubiprostone, The risk or severity of adverse effects can be increased when Lubiprostone is combined with Linaclotide.]
[C03CC01, ethacrynic acid, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Linaclotide.]
[C08EX01, lidoflazine, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Lidoflazine.]
[C03DB01, amiloride, The risk or severity of adverse effects can be increased when Amiloride is combined with Linaclotide.]
[A07DA03, loperamide, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Loperamide.]
[G04BX01, magnesium hydroxide, The risk or severity of adverse effects can be increased when Linaclotide is combined with Magnesium hydroxide.]
[A12CC10, magnesium oxide, The risk or severity of adverse effects can be increased when Magnesium oxide is combined with Linaclotide.]
[V04CC02, magnesium sulfate, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Magnesium sulfate.]
[V04CX04, mannitol, The risk or severity of adverse effects can be increased when Mannitol is combined with Linaclotide.]
[N06AA21, maprotiline, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Maprotiline.]
[C02BB01, mecamylamine, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Mecamylamine.]
[R06AE05, meclizine, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Meclizine.]
[A06AB07, cascara sagrada, The risk or severity of adverse effects can be increased when Linaclotide is combined with Frangula purshiana bark.]
[C03BA05, mefruside, The risk or severity of adverse effects can be increased when Mefruside is combined with Linaclotide.]
[N02AB02, meperidine, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Meperidine.]
[N03AA01, mephobarbital, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Methylphenobarbital.]
[N02AX05, meptazinol, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Meptazinol.]
[C03BC01, mersalyl, The risk or severity of adverse effects can be increased when Mersalyl is combined with Linaclotide.]
[N07BC02, methadone, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Methadone.]
[A03AB07, methantheline, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Methantheline.]
[N03AA30, metharbital, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Metharbital.]
[S01EC05, methazolamide, The risk or severity of adverse effects can be increased when Methazolamide is combined with Linaclotide.]
[N02BG08, ziconotide, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Ziconotide.]
[N05AA02, methotrimeprazine, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Methotrimeprazine.]
[C03AA08, methyclothiazide, The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Linaclotide.]
[A06AC06, methylcellulose, The risk or severity of adverse effects can be increased when Linaclotide is combined with Methylcellulose.]
[C03BA08, metolazone, The risk or severity of adverse effects can be increased when Metolazone is combined with Linaclotide.]
[A06AA01, mineral oil, The risk or severity of adverse effects can be increased when Linaclotide is combined with Mineral oil.]
[C01BD01, amiodarone, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Amiodarone.]
[N06AA09, amitriptyline, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Amitriptyline.]
[N02AA01, morphine, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Morphine.]
[M03AC03, vecuronium, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Vecuronium.]
[N05CA02, amobarbital, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Amobarbital.]
[R03BB01, ipratropium bromide, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Ipratropium.]
[N06AA17, amoxapine, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Amoxapine.]
[N02AF02, nalbuphine, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Nalbuphine.]
[N07BB04, naltrexone, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Naltrexone.]
[N01AH06, remifentanil, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Remifentanil.]
[C08CA04, nicardipine, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Nicardipine.]
[C08CA05, nifedipine, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Nifedipine.]
[C08CA06, nimodipine, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Nimodipine.]
[C08CA07, nisoldipine, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Nisoldipine.]
[C08CA08, nitrendipine, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Nitrendipine.]
[N06AA10, nortriptyline, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Nortriptyline.]
[G02CA02, nylidrin, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Nylidrin.]
[N02AA02, opium, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Opium.]
[N02AA05, oxycodone, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Oxycodone.]
[N02AA11, oxymorphone, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Oxymorphone.]
[A03AB03, oxyphenonium, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Oxyphenonium.]
[N02AX06, tapentadol, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Tapentadol.]
[M03AC01, pancuronium, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Pancuronium.]
[G04BD11, fesoterodine, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Fesoterodine.]
[N05AG03, penfluridol, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Penfluridol.]
[N02AD01, pentazocine, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Pentazocine.]
[N05CA01, pentobarbital, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Pentobarbital.]
[C08EX02, perhexiline, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Perhexiline.]
[N02AD02, phenazocine, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Phenazocine.]
[N03AA02, phenobarbital, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Phenobarbital.]
[A06AB01, oxyphenisatin, The risk or severity of adverse effects can be increased when Oxyphenisatin is combined with Linaclotide.]
[N01AH04, phenoperidine, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Phenoperidine.]
[C08CX01, mibefradil, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Mibefradil.]
[A02BX03, pirenzepine, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Pirenzepine.]
[N02AC03, pirinitramide, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Piritramide.]
[N02CX01, pizotyline, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Pizotifen.]
[A06AD15, polyethylene glycols, The risk or severity of adverse effects can be increased when Linaclotide is combined with Polyethylene glycol.]
[C03AA05, polythiazide, The risk or severity of adverse effects can be increased when Polythiazide is combined with Linaclotide.]
[C01DX02, prenylamine, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Prenylamine.]
[N03AA03, primidone, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Primidone.]
[S01HA05, procaine, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Procaine.]
[N04AA04, procyclidine, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Procyclidine.]
[N05AA03, promazine, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Promazine.]
[R06AD02, promethazine, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Promethazine.]
[A03AB05, propantheline, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Propantheline.]
[N05CM06, propiomazine, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Propiomazine.]
[N02AC04, propoxyphene, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Dextropropoxyphene.]
[N05AX12, aripiprazole, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Aripiprazole.]
[A03AB15, diphemanil, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Diphemanil.]
[A03AB09, isopropamide, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Isopropamide.]
[S01FA03, methscopolamine, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Methscopolamine.]
[N05CA07, talbutal, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Talbutal.]
[C01BA01, quinidine, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Quinidine.]
[S01FA02, scopolamine, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Scopolamine.]
[N05CA06, secobarbital, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Secobarbital.]
[V04CC01, sorbitol, The risk or severity of adverse effects can be increased when Sorbitol is combined with Linaclotide.]
[C03DA01, spironolactone, The risk or severity of adverse effects can be increased when Spironolactone is combined with Linaclotide.]
